{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37463901", "DateCompleted": {"Year": "2023", "Month": "07", "Day": "21"}, "DateRevised": {"Year": "2023", "Month": "09", "Day": "28"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "07", "Day": "18"}], "Language": ["eng"], "ELocationID": ["4313", "10.1038/s41467-023-39935-y"], "Journal": {"ISSN": "2041-1723", "JournalIssue": {"Volume": "14", "Issue": "1", "PubDate": {"Year": "2023", "Month": "Jul", "Day": "18"}}, "Title": "Nature communications", "ISOAbbreviation": "Nat Commun"}, "ArticleTitle": "Distinct shared and compartment-enriched oncogenic networks drive primary versus metastatic breast cancer.", "Pagination": {"StartPage": "4313", "MedlinePgn": "4313"}, "Abstract": {"AbstractText": ["Metastatic breast-cancer is a major cause of death in women worldwide, yet the relationship between oncogenic drivers that promote metastatic versus primary cancer is still contentious. To elucidate this relationship in treatment-naive animals, we hereby describe mammary-specific transposon-mutagenesis screens in female mice together with loss-of-function Rb, which is frequently inactivated in breast-cancer. We report gene-centric common insertion-sites (gCIS) that are enriched in primary-tumors, in metastases or shared by both compartments. Shared-gCIS comprise a major MET-RAS network, whereas metastasis-gCIS form three additional hubs: Rho-signaling, Ubiquitination and RNA-processing. Pathway analysis of four clinical cohorts with paired primary-tumors and metastases reveals similar organization in human breast-cancer with subtype-specific shared-drivers (e.g. RB1-loss, TP53-loss, high MET, RAS, ER), primary-enriched (EGFR, TGF\u03b2 and STAT3) and metastasis-enriched (RHO, PI3K) oncogenic signaling. Inhibitors of RB1-deficiency or MET plus RHO-signaling cooperate to block cell migration and drive tumor cell-death. Thus, targeting shared- and metastasis- but not primary-enriched derivers offers a rational avenue to prevent metastatic breast-cancer."], "CopyrightInformation": "\u00a9 2023. The Author(s)."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toronto General Research Institute - University Health Network, 101 College Street, Max Bell Research Centre, suite 5R406, Toronto, ON, M5G 1L7, Canada."}], "LastName": "Jiang", "ForeName": "Zhe", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toronto General Research Institute - University Health Network, 101 College Street, Max Bell Research Centre, suite 5R406, Toronto, ON, M5G 1L7, Canada."}], "LastName": "Ju", "ForeName": "YoungJun", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toronto General Research Institute - University Health Network, 101 College Street, Max Bell Research Centre, suite 5R406, Toronto, ON, M5G 1L7, Canada."}], "LastName": "Ali", "ForeName": "Amjad", "Initials": "A"}, {"Identifier": ["0000-0002-3443-3088"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toronto General Research Institute - University Health Network, 101 College Street, Max Bell Research Centre, suite 5R406, Toronto, ON, M5G 1L7, Canada."}, {"Identifier": [], "Affiliation": "Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada."}], "LastName": "Chung", "ForeName": "Philip E D", "Initials": "PED"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada."}, {"Identifier": [], "Affiliation": "Program in Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada."}, {"Identifier": [], "Affiliation": "The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada."}], "LastName": "Skowron", "ForeName": "Patryk", "Initials": "P"}, {"Identifier": ["0000-0002-5434-287X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toronto General Research Institute - University Health Network, 101 College Street, Max Bell Research Centre, suite 5R406, Toronto, ON, M5G 1L7, Canada."}], "LastName": "Wang", "ForeName": "Dong-Yu", "Initials": "DY"}, {"Identifier": ["0009-0003-7880-7584"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toronto General Research Institute - University Health Network, 101 College Street, Max Bell Research Centre, suite 5R406, Toronto, ON, M5G 1L7, Canada."}, {"Identifier": [], "Affiliation": "Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada."}], "LastName": "Shrestha", "ForeName": "Mariusz", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toronto General Research Institute - University Health Network, 101 College Street, Max Bell Research Centre, suite 5R406, Toronto, ON, M5G 1L7, Canada."}], "LastName": "Li", "ForeName": "Huiqin", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Donnelly Centre, University of Toronto, Toronto, ON, Canada."}], "LastName": "Liu", "ForeName": "Jeff C", "Initials": "JC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toronto General Research Institute - University Health Network, 101 College Street, Max Bell Research Centre, suite 5R406, Toronto, ON, M5G 1L7, Canada."}, {"Identifier": [], "Affiliation": "Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada."}], "LastName": "Vorobieva", "ForeName": "Ioulia", "Initials": "I"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toronto General Research Institute - University Health Network, 101 College Street, Max Bell Research Centre, suite 5R406, Toronto, ON, M5G 1L7, Canada."}, {"Identifier": [], "Affiliation": "Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada."}], "LastName": "Ghanbari-Azarnier", "ForeName": "Ronak", "Initials": "R"}, {"Identifier": ["0000-0003-0568-9372"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toronto General Research Institute - University Health Network, 101 College Street, Max Bell Research Centre, suite 5R406, Toronto, ON, M5G 1L7, Canada."}], "LastName": "Mwewa", "ForeName": "Ethel", "Initials": "E"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada."}], "LastName": "Koritzinsky", "ForeName": "Marianne", "Initials": "M"}, {"Identifier": ["0000-0002-9020-6074"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Key laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academic of Sciences, Guiyang, Guizhou, 550014, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, 550025, China."}], "LastName": "Ben-David", "ForeName": "Yaacov", "Initials": "Y"}, {"Identifier": ["0000-0003-3731-5797"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Lunenfeld-Tanenbaum Research Institute, Sinai Health System, 600 University Avenue, Toronto, ON, Canada."}], "LastName": "Woodgett", "ForeName": "James R", "Initials": "JR"}, {"Identifier": ["0000-0001-9827-2247"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Lineberger Comprehensive Cancer Center, Departments of Genetics and Pathology, University of North Carolina, Chapel Hill, NC, 27599, USA."}], "LastName": "Perou", "ForeName": "Charles M", "Initials": "CM"}, {"Identifier": ["0000-0002-8561-4911"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pathology, Carver College of Medicine, The University of Iowa, Iowa City, Iowa, 52242, USA."}], "LastName": "Dupuy", "ForeName": "Adam", "Initials": "A"}, {"Identifier": ["0000-0003-0185-8861"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Donnelly Centre, University of Toronto, Toronto, ON, Canada."}, {"Identifier": [], "Affiliation": "Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada."}], "LastName": "Bader", "ForeName": "Gary D", "Initials": "GD"}, {"Identifier": ["0000-0003-0189-3202"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Program in Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada."}, {"Identifier": [], "Affiliation": "Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada."}], "LastName": "Egan", "ForeName": "Sean E", "Initials": "SE"}, {"Identifier": ["0000-0001-7009-3466"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada."}, {"Identifier": [], "Affiliation": "Program in Developmental & Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada."}, {"Identifier": [], "Affiliation": "The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada."}], "LastName": "Taylor", "ForeName": "Michael D", "Initials": "MD"}, {"Identifier": ["0000-0001-6104-6094"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toronto General Research Institute - University Health Network, 101 College Street, Max Bell Research Centre, suite 5R406, Toronto, ON, M5G 1L7, Canada. eldad.zacksenhaus@utoronto.ca."}, {"Identifier": [], "Affiliation": "Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada. eldad.zacksenhaus@utoronto.ca."}, {"Identifier": [], "Affiliation": "Department of Medicine, University of Toronto, Toronto, ON, Canada. eldad.zacksenhaus@utoronto.ca."}], "LastName": "Zacksenhaus", "ForeName": "Eldad", "Initials": "E"}], "GrantList": [{"GrantID": "P30 CA086862", "Acronym": "CA", "Agency": "NCI NIH HHS", "Country": "United States"}, {"GrantID": "R01 CA148761", "Acronym": "CA", "Agency": "NCI NIH HHS", "Country": "United States"}], "PublicationTypeList": ["Journal Article", "Research Support, N.I.H., Extramural", "Research Support, U.S. Gov't, Non-P.H.S.", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Nat Commun", "NlmUniqueID": "101528555", "ISSNLinking": "2041-1723"}, "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": ["pathology"], "DescriptorName": "Breast Neoplasms"}, {"QualifierName": [], "DescriptorName": "Signal Transduction"}, {"QualifierName": [], "DescriptorName": "Neoplasm Metastasis"}], "CoiStatement": "C.M.P. is an equity stockholder and consultant of BioClassifier LLC; C.M.P. is also listed as an inventor on patent applications for the Breast PAM50 Subtyping assay. There is no direct relationship between these PAM50 patents and the Intellectual Property and content of this study. The other authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275\u2013292. doi: 10.1016/j.cell.2011.09.024.", "ArticleIdList": ["10.1016/j.cell.2011.09.024", "PMC3261217", "22000009"]}, {"Citation": "Nathanson, S. D. et al. Mechanisms of breast cancer metastasis. Clin. Exp. Metastasis39, 117\u2013137 (2022).", "ArticleIdList": ["PMC8568733", "33950409"]}, {"Citation": "Esposito M, Ganesan S, Kang Y. Emerging strategies for treating metastasis. Nat. Cancer. 2021;2:258\u2013270. doi: 10.1038/s43018-021-00181-0.", "ArticleIdList": ["10.1038/s43018-021-00181-0", "PMC8064405", "33899000"]}, {"Citation": "Gui P, Bivona TG. Evolution of metastasis: new tools and insights. Trends Cancer. 2022;8:98\u2013109. doi: 10.1016/j.trecan.2021.11.002.", "ArticleIdList": ["10.1016/j.trecan.2021.11.002", "34872888"]}, {"Citation": "Bernards R, Weinberg RA. A progression puzzle. Nature. 2002;418:823. doi: 10.1038/418823a.", "ArticleIdList": ["10.1038/418823a", "12192390"]}, {"Citation": "Zacksenhaus, E. & Egan, S. E. Progression to metastasis of solid cancer. Cancers13, 717\u2013725 (2021).", "ArticleIdList": ["PMC7916396", "33578666"]}, {"Citation": "Siegel MB, et al. Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J. Clin. Investig. 2018;128:1371\u20131383. doi: 10.1172/JCI96153.", "ArticleIdList": ["10.1172/JCI96153", "PMC5873890", "29480819"]}, {"Citation": "van Dessel LF, et al. The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact. Nat. Commun. 2019;10:5251. doi: 10.1038/s41467-019-13084-7.", "ArticleIdList": ["10.1038/s41467-019-13084-7", "PMC6868175", "31748536"]}, {"Citation": "Robinson, D. R. et al. Integrative clinical genomics of metastatic cancer. Nature548, 297\u2013303 (2017).", "ArticleIdList": ["PMC5995337", "28783718"]}, {"Citation": "Savas P, et al. The subclonal architecture of metastatic breast cancer: results from a prospective community-based rapid autopsy program \u201cCASCADE\u201d. PLoS Med. 2016;13:e1002204. doi: 10.1371/journal.pmed.1002204.", "ArticleIdList": ["10.1371/journal.pmed.1002204", "PMC5189956", "28027312"]}, {"Citation": "Paul MR, et al. Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets. J. Clin. Investig. 2020;130:4252\u20134265.", "ArticleIdList": ["PMC7410083", "32657779"]}, {"Citation": "Wu X, et al. Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature. 2012;482:529\u2013533. doi: 10.1038/nature10825.", "ArticleIdList": ["10.1038/nature10825", "PMC3288636", "22343890"]}, {"Citation": "Hakem A, et al. RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev. 2005;19:1974\u20131979. doi: 10.1101/gad.1310805.", "ArticleIdList": ["10.1101/gad.1310805", "PMC1199568", "16107613"]}, {"Citation": "Ishaque N, et al. Whole genome sequencing puts forward hypotheses on metastasis evolution and therapy in colorectal cancer. Nat. Commun. 2018;9:4782. doi: 10.1038/s41467-018-07041-z.", "ArticleIdList": ["10.1038/s41467-018-07041-z", "PMC6235880", "30429477"]}, {"Citation": "Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer. 2009;9:274\u2013284. doi: 10.1038/nrc2622.", "ArticleIdList": ["10.1038/nrc2622", "19308067"]}, {"Citation": "Morrissy AS, et al. Spatial heterogeneity in medulloblastoma. Nat. Genet. 2017;49:780\u2013788. doi: 10.1038/ng.3838.", "ArticleIdList": ["10.1038/ng.3838", "PMC5553617", "28394352"]}, {"Citation": "Rossi D, et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood. 2014;123:2139\u20132147. doi: 10.1182/blood-2013-11-539726.", "ArticleIdList": ["10.1182/blood-2013-11-539726", "PMC4017291", "24501221"]}, {"Citation": "Moriarity BS, Largaespada DA. Sleeping Beauty transposon insertional mutagenesis based mouse models for cancer gene discovery. Curr. Opin. Genet Dev. 2015;30:66\u201372. doi: 10.1016/j.gde.2015.04.007.", "ArticleIdList": ["10.1016/j.gde.2015.04.007", "PMC4900178", "26051241"]}, {"Citation": "Guimaraes-Young A, Feddersen CR, Dupuy AJ. Sleeping Beauty mouse models of cancer: microenvironmental influences on cancer genetics. Front Oncol. 2019;9:611. doi: 10.3389/fonc.2019.00611.", "ArticleIdList": ["10.3389/fonc.2019.00611", "PMC6629774", "31338332"]}, {"Citation": "Dupuy AJ, Akagi K, Largaespada DA, Copeland NG, Jenkins NA. Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature. 2005;436:221\u2013226. doi: 10.1038/nature03691.", "ArticleIdList": ["10.1038/nature03691", "16015321"]}, {"Citation": "Uren A, Berns A. Jump-starting cancer gene discovery. Nat. Biotechnol. 2009;27:251\u2013252. doi: 10.1038/nbt0309-251.", "ArticleIdList": ["10.1038/nbt0309-251", "19270673"]}, {"Citation": "Starr TK, et al. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science. 2009;323:1747\u20131750. doi: 10.1126/science.1163040.", "ArticleIdList": ["10.1126/science.1163040", "PMC2743559", "19251594"]}, {"Citation": "Keng VW, et al. A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat. Biotechnol. 2009;27:264\u2013274. doi: 10.1038/nbt.1526.", "ArticleIdList": ["10.1038/nbt.1526", "PMC2712727", "19234449"]}, {"Citation": "Collier LS, Carlson CM, Ravimohan S, Dupuy AJ, Largaespada DA. Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature. 2005;436:272\u2013276. doi: 10.1038/nature03681.", "ArticleIdList": ["10.1038/nature03681", "16015333"]}, {"Citation": "Suarez-Cabrera C, et al. A transposon-based analysis reveals RASA1 is involved in triple-negative breast cancer. Cancer Res. 2017;77:1357\u20131368. doi: 10.1158/0008-5472.CAN-16-1586.", "ArticleIdList": ["10.1158/0008-5472.CAN-16-1586", "28108518"]}, {"Citation": "Miao K, et al. NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation. Nat. Commun. 2020;11:3256. doi: 10.1038/s41467-020-16936-9.", "ArticleIdList": ["10.1038/s41467-020-16936-9", "PMC7320176", "32591500"]}, {"Citation": "Takeda H, et al. Sleeping Beauty transposon mutagenesis identifies genes that cooperate with mutant Smad4 in gastric cancer development. Proc. Natl. Acad. Sci. USA. 2016;113:E2057\u2013E2065. doi: 10.1073/pnas.1603223113.", "ArticleIdList": ["10.1073/pnas.1603223113", "PMC4833248", "27006499"]}, {"Citation": "Schachter NF, et al. Single allele loss-of-function mutations select and sculpt conditional cooperative networks in breast cancer. Nat. Commun. 2021;12:5238. doi: 10.1038/s41467-021-25467-w.", "ArticleIdList": ["10.1038/s41467-021-25467-w", "PMC8413298", "34475389"]}, {"Citation": "Ahmad I, et al. Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer. Proc. Natl. Acad. Sci. USA. 2016;113:8290\u20138295. doi: 10.1073/pnas.1601571113.", "ArticleIdList": ["10.1073/pnas.1601571113", "PMC4961202", "27357679"]}, {"Citation": "Moriarity BS, et al. A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis. Nat. Genet. 2015;47:615\u2013624. doi: 10.1038/ng.3293.", "ArticleIdList": ["10.1038/ng.3293", "PMC4767150", "25961939"]}, {"Citation": "Jiang Z, et al. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle. 2011;10:1563\u20131570. doi: 10.4161/cc.10.10.15703.", "ArticleIdList": ["10.4161/cc.10.10.15703", "21502814"]}, {"Citation": "Zacksenhaus E, et al. Mitochondrial OXPHOS induced by RB1 deficiency in breast cancer: implications for anabolic metabolism, stemness, and metastasis. Trends Cancer. 2017;3:768\u2013779. doi: 10.1016/j.trecan.2017.09.002.", "ArticleIdList": ["10.1016/j.trecan.2017.09.002", "29120753"]}, {"Citation": "Jiang Z, et al. Hypophosphorylated pRb knock-in mice exhibit hallmarks of aging and vitamin C-preventable diabetes. EMBO J. 2022;41:e106825. doi: 10.15252/embj.2020106825.", "ArticleIdList": ["10.15252/embj.2020106825", "PMC8844977", "35023164"]}, {"Citation": "Koboldt DC, et al. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61\u201370. doi: 10.1038/nature11412.", "ArticleIdList": ["10.1038/nature11412", "PMC3465532", "23000897"]}, {"Citation": "Nik-Zainal S, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534:47\u201354. doi: 10.1038/nature17676.", "ArticleIdList": ["10.1038/nature17676", "PMC4910866", "27135926"]}, {"Citation": "Jones RA, et al. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation. J. Clin. Investig. 2016;126:3739\u20133757. doi: 10.1172/JCI81568.", "ArticleIdList": ["10.1172/JCI81568", "PMC5096803", "27571409"]}, {"Citation": "Dietlein F, et al. Identification of cancer driver genes based on nucleotide context. Nat. Genet. 2020;52:208\u2013218. doi: 10.1038/s41588-019-0572-y.", "ArticleIdList": ["10.1038/s41588-019-0572-y", "PMC7031046", "32015527"]}, {"Citation": "Jiang Z, et al. Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J. Clin. Investig. 2010;120:3296\u20133309. doi: 10.1172/JCI41490.", "ArticleIdList": ["10.1172/JCI41490", "PMC2929714", "20679727"]}, {"Citation": "Herschkowitz JI, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007;8:R76. doi: 10.1186/gb-2007-8-5-r76.", "ArticleIdList": ["10.1186/gb-2007-8-5-r76", "PMC1929138", "17493263"]}, {"Citation": "Dupuy AJ. Transposon-based screens for cancer gene discovery in mouse models. Semin Cancer Biol. 2010;20:261\u2013268. doi: 10.1016/j.semcancer.2010.05.003.", "ArticleIdList": ["10.1016/j.semcancer.2010.05.003", "PMC2940989", "20478384"]}, {"Citation": "Dupuy AJ, et al. A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice. Cancer Res. 2009;69:8150\u20138156. doi: 10.1158/0008-5472.CAN-09-1135.", "ArticleIdList": ["10.1158/0008-5472.CAN-09-1135", "PMC3700628", "19808965"]}, {"Citation": "Koudijs MJ, et al. High-throughput semiquantitative analysis of insertional mutations in heterogeneous tumors. Genome Res. 2011;21:2181\u20132189. doi: 10.1101/gr.112763.110.", "ArticleIdList": ["10.1101/gr.112763.110", "PMC3227106", "21852388"]}, {"Citation": "Brett BT, et al. Novel molecular and computational methods improve the accuracy of insertion site analysis in Sleeping Beauty-induced tumors. PLoS ONE. 2011;6:e24668. doi: 10.1371/journal.pone.0024668.", "ArticleIdList": ["10.1371/journal.pone.0024668", "PMC3172244", "21931803"]}, {"Citation": "Priestley P, et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 2019;575:210\u2013216. doi: 10.1038/s41586-019-1689-y.", "ArticleIdList": ["10.1038/s41586-019-1689-y", "PMC6872491", "31645765"]}, {"Citation": "Aceto N, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014;158:1110\u20131122. doi: 10.1016/j.cell.2014.07.013.", "ArticleIdList": ["10.1016/j.cell.2014.07.013", "PMC4149753", "25171411"]}, {"Citation": "Lee EYHP, et al. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature. 1992;359:288\u2013294. doi: 10.1038/359288a0.", "ArticleIdList": ["10.1038/359288a0", "1406932"]}, {"Citation": "Jacks T, et al. Effects of an Rb mutation in the mouse. Nature. 1992;359:295\u2013300. doi: 10.1038/359295a0.", "ArticleIdList": ["10.1038/359295a0", "1406933"]}, {"Citation": "Marko TA, et al. Slit-Robo GTPase-activating protein 2 as a metastasis suppressor in osteosarcoma. Sci. Rep. 2016;6:39059. doi: 10.1038/srep39059.", "ArticleIdList": ["10.1038/srep39059", "PMC5155223", "27966608"]}, {"Citation": "East MP, Asquith CRM. CDC42BPA/MRCKalpha: a kinase target for brain, ovarian and skin cancers. Nat. Rev. Drug Discov. 2021;20:167. doi: 10.1038/d41573-021-00023-9.", "ArticleIdList": ["10.1038/d41573-021-00023-9", "33558670"]}, {"Citation": "Kurisu S, Suetsugu S, Yamazaki D, Yamaguchi H, Takenawa T. Rac-WAVE2 signaling is involved in the invasive and metastatic phenotypes of murine melanoma cells. Oncogene. 2005;24:1309\u20131319. doi: 10.1038/sj.onc.1208177.", "ArticleIdList": ["10.1038/sj.onc.1208177", "15608687"]}, {"Citation": "Lockwood WW, Chandel SK, Stewart GL, Erdjument-Bromage H, Beverly LJ. The novel ubiquitin ligase complex, SCF(Fbxw4), interacts with the COP9 signalosome in an F-box dependent manner, is mutated, lost and under-expressed in human cancers. PLoS ONE. 2013;8:e63610. doi: 10.1371/journal.pone.0063610.", "ArticleIdList": ["10.1371/journal.pone.0063610", "PMC3642104", "23658844"]}, {"Citation": "Song Y, et al. The emerging role of SPOP protein in tumorigenesis and cancer therapy. Mol. Cancer. 2020;19:2. doi: 10.1186/s12943-019-1124-x.", "ArticleIdList": ["10.1186/s12943-019-1124-x", "PMC6942384", "31901237"]}, {"Citation": "Duhamel S, et al. The E3 ubiquitin ligase HectD1 suppresses EMT and metastasis by targeting the +TIP ACF7 for degradation. Cell Rep. 2018;22:1016\u20131030. doi: 10.1016/j.celrep.2017.12.096.", "ArticleIdList": ["10.1016/j.celrep.2017.12.096", "29386124"]}, {"Citation": "Pan Z, Bao J, Zhang L, Wei S. UBE2D3 activates SHP-2 ubiquitination to promote glycolysis and proliferation of glioma via regulating STAT3 signaling pathway. Front. Oncol. 2021;11:674286. doi: 10.3389/fonc.2021.674286.", "ArticleIdList": ["10.3389/fonc.2021.674286", "PMC8236812", "34195079"]}, {"Citation": "Chan SL, et al. CPSF30 and Wdr33 directly bind to AAUAAA in mammalian mRNA 3\u2019 processing. Genes Dev. 2014;28:2370\u20132380. doi: 10.1101/gad.250993.114.", "ArticleIdList": ["10.1101/gad.250993.114", "PMC4215182", "25301780"]}, {"Citation": "Li J, et al. CDC5L promotes hTERT expression and colorectal tumor growth. Cell Physiol. Biochem. 2017;41:2475\u20132488. doi: 10.1159/000475916.", "ArticleIdList": ["10.1159/000475916", "28472785"]}, {"Citation": "Liu W, et al. PRPF6 promotes androgen receptor/androgen receptor-variant 7 actions in castration-resistant prostate cancer cells. Int. J. Biol. Sci. 2021;17:188\u2013203. doi: 10.7150/ijbs.50810.", "ArticleIdList": ["10.7150/ijbs.50810", "PMC7757026", "33390843"]}, {"Citation": "Yeh HW, et al. PSPC1 mediates TGF-beta1 autocrine signalling and Smad2/3 target switching to promote EMT, stemness and metastasis. Nat. Cell Biol. 2018;20:479\u2013491. doi: 10.1038/s41556-018-0062-y.", "ArticleIdList": ["10.1038/s41556-018-0062-y", "29593326"]}, {"Citation": "Reimand J, Arak T, Vilo J. g:Profiler\u2013a web server for functional interpretation of gene lists (2011 update) Nucleic Acids Res. 2011;39:W307\u2013W315. doi: 10.1093/nar/gkr378.", "ArticleIdList": ["10.1093/nar/gkr378", "PMC3125778", "21646343"]}, {"Citation": "Baker A, et al. Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival. Oncogene. 2018;37:4489\u20134504. doi: 10.1038/s41388-018-0251-y.", "ArticleIdList": ["10.1038/s41388-018-0251-y", "PMC9115842", "29743588"]}, {"Citation": "Zhang X, et al. Notch1 promotes glioma cell migration and invasion by stimulating beta-catenin and NF-kappaB signaling via AKT activation. Cancer Sci. 2012;103:181\u2013190. doi: 10.1111/j.1349-7006.2011.02154.x.", "ArticleIdList": ["10.1111/j.1349-7006.2011.02154.x", "22093097"]}, {"Citation": "Raviraj V, et al. Regulation of ROCK1 via Notch1 during breast cancer cell migration into dense matrices. BMC Cell Biol. 2012;13:12. doi: 10.1186/1471-2121-13-12.", "ArticleIdList": ["10.1186/1471-2121-13-12", "PMC3520698", "22583596"]}, {"Citation": "Ho-Yen CM, Jones JL, Kermorgant S. The clinical and functional significance of c-Met in breast cancer: a review. Breast Cancer Res. 2015;17:52. doi: 10.1186/s13058-015-0547-6.", "ArticleIdList": ["10.1186/s13058-015-0547-6", "PMC4389345", "25887320"]}, {"Citation": "Zhang Y, et al. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol. Cancer. 2018;17:45. doi: 10.1186/s12943-018-0796-y.", "ArticleIdList": ["10.1186/s12943-018-0796-y", "PMC5817860", "29455668"]}, {"Citation": "Giltnane JM, Balko JM. Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer. Discov. Med. 2014;17:275\u2013283.", "ArticleIdList": ["24882719"]}, {"Citation": "Singh S, Smith MJ. RAS GTPase signalling to alternative effector pathways. Biochem. Soc. Trans. 2020;48:2241\u20132252. doi: 10.1042/BST20200506.", "ArticleIdList": ["10.1042/BST20200506", "33125484"]}, {"Citation": "Wang M, et al. Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers. Ann. Diagn. Pathol. 2018;35:69\u201376. doi: 10.1016/j.anndiagpath.2018.04.004.", "ArticleIdList": ["10.1016/j.anndiagpath.2018.04.004", "29843069"]}, {"Citation": "Kaposi-Novak P, et al. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J. Clin. Investig. 2006;116:1582\u20131595. doi: 10.1172/JCI27236.", "ArticleIdList": ["10.1172/JCI27236", "PMC1462944", "16710476"]}, {"Citation": "Lehmann BD, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Investig. 2011;121:2750\u20132767. doi: 10.1172/JCI45014.", "ArticleIdList": ["10.1172/JCI45014", "PMC3127435", "21633166"]}, {"Citation": "Wang DY, Gendoo DMA, Ben-David Y, Woodgett JR, Zacksenhaus E. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling. Breast Cancer Res. 2019;21:18. doi: 10.1186/s13058-019-1098-z.", "ArticleIdList": ["10.1186/s13058-019-1098-z", "PMC6357448", "30704524"]}, {"Citation": "Wang DY, Jiang Z, Ben-David Y, Woodgett JR, Zacksenhaus E. Molecular stratification within triple-negative breast cancer subtypes. Sci. Rep. 2019;9:19107. doi: 10.1038/s41598-019-55710-w.", "ArticleIdList": ["10.1038/s41598-019-55710-w", "PMC6911070", "31836816"]}, {"Citation": "Rody A, et al. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res. 2011;13:R97. doi: 10.1186/bcr3035.", "ArticleIdList": ["10.1186/bcr3035", "PMC3262210", "21978456"]}, {"Citation": "Ghandi M, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019;569:503\u2013508. doi: 10.1038/s41586-019-1186-3.", "ArticleIdList": ["10.1038/s41586-019-1186-3", "PMC6697103", "31068700"]}, {"Citation": "Prat A, et al. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. Breast Cancer Res. Treat. 2013;142:237\u2013255. doi: 10.1007/s10549-013-2743-3.", "ArticleIdList": ["10.1007/s10549-013-2743-3", "PMC3832776", "24162158"]}, {"Citation": "Curtis C, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346\u2013352. doi: 10.1038/nature10983.", "ArticleIdList": ["10.1038/nature10983", "PMC3440846", "22522925"]}, {"Citation": "Ellis MJ, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486:353\u2013360. doi: 10.1038/nature11143.", "ArticleIdList": ["10.1038/nature11143", "PMC3383766", "22722193"]}, {"Citation": "Shah SP, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486:395\u2013399. doi: 10.1038/nature10933.", "ArticleIdList": ["10.1038/nature10933", "PMC3863681", "22495314"]}, {"Citation": "Stephens PJ, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012;486:400\u2013404. doi: 10.1038/nature11017.", "ArticleIdList": ["10.1038/nature11017", "PMC3428862", "22722201"]}, {"Citation": "Lawrence MS, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505:495\u2013501. doi: 10.1038/nature12912.", "ArticleIdList": ["10.1038/nature12912", "PMC4048962", "24390350"]}, {"Citation": "Thompson BJ, et al. Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7. J. Exp. Med. 2008;205:1395\u20131408. doi: 10.1084/jem.20080277.", "ArticleIdList": ["10.1084/jem.20080277", "PMC2413036", "18474632"]}, {"Citation": "Pereira, B. et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat. Commun.7, 11479 (2016).", "ArticleIdList": ["PMC4866047", "27161491"]}, {"Citation": "Liu JC, et al. Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K. EMBO Mol. Med. 2014;6:1542\u20131560. doi: 10.15252/emmm.201404402.", "ArticleIdList": ["10.15252/emmm.201404402", "PMC4287974", "25330770"]}, {"Citation": "Liu JC, et al. Identification of CDC25 as a common therapeutic target for triple-negative breast cancer. Cell Rep. 2018;23:112\u2013126. doi: 10.1016/j.celrep.2018.03.039.", "ArticleIdList": ["10.1016/j.celrep.2018.03.039", "PMC9357459", "29617654"]}, {"Citation": "Zuo Y, Wu Y, Chakraborty C. Cdc42 negatively regulates intrinsic migration of highly aggressive breast cancer cells. J. Cell Physiol. 2012;227:1399\u20131407. doi: 10.1002/jcp.22853.", "ArticleIdList": ["10.1002/jcp.22853", "21618528"]}, {"Citation": "Wilkinson S, Paterson HF, Marshall CJ. Cdc42-MRCK and Rho-ROCK signalling cooperate in myosin phosphorylation and cell invasion. Nat. Cell Biol. 2005;7:255\u2013261. doi: 10.1038/ncb1230.", "ArticleIdList": ["10.1038/ncb1230", "15723050"]}, {"Citation": "Gatza ML, et al. A pathway-based classification of human breast cancer. Proc. Natl. Acad. Sci. USA. 2010;107:6994\u20136999. doi: 10.1073/pnas.0912708107.", "ArticleIdList": ["10.1073/pnas.0912708107", "PMC2872436", "20335537"]}, {"Citation": "Andrechek ER, et al. Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. Proc. Natl. Acad. Sci. USA. 2009;106:16387\u201316392. doi: 10.1073/pnas.0901250106.", "ArticleIdList": ["10.1073/pnas.0901250106", "PMC2752567", "19805309"]}, {"Citation": "Garcia-Recio S, et al. FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. J. Clin. Investig. 2020;130:4871\u20134887. doi: 10.1172/JCI130323.", "ArticleIdList": ["10.1172/JCI130323", "PMC7456247", "32573490"]}, {"Citation": "Tobin NP, et al. PAM50 provides prognostic information when applied to the lymph node metastases of advanced breast cancer patients. Clin. Cancer Res. 2017;23:7225\u20137231. doi: 10.1158/1078-0432.CCR-17-2301.", "ArticleIdList": ["10.1158/1078-0432.CCR-17-2301", "PMC5822712", "28972041"]}, {"Citation": "Padua D, Massague J. Roles of TGFbeta in metastasis. Cell Res. 2009;19:89\u2013102. doi: 10.1038/cr.2008.316.", "ArticleIdList": ["10.1038/cr.2008.316", "19050696"]}, {"Citation": "Seoane, J. & Gomis, R. R. TGF-beta family signaling in tumor suppression and cancer progression. Cold Spring Harb. Perspect. Biol.9, a022277 (2017).", "ArticleIdList": ["PMC5710110", "28246180"]}, {"Citation": "Tian M, Schiemann WP. The TGF-beta paradox in human cancer: an update. Future Oncol. 2009;5:259\u2013271. doi: 10.2217/14796694.5.2.259.", "ArticleIdList": ["10.2217/14796694.5.2.259", "PMC2710615", "19284383"]}, {"Citation": "Ali, R. & Wendt, M. K. The paradoxical functions of EGFR during breast cancer progression. Sig. Transduct. Target. Ther.2, 16042 (2017).", "ArticleIdList": ["PMC5397119", "28435746"]}, {"Citation": "Jones LM, et al. STAT3 Establishes an Immunosuppressive Microenvironment during the Early Stages of Breast Carcinogenesis to Promote Tumor Growth and Metastasis. Cancer Res. 2016;76:1416\u20131428. doi: 10.1158/0008-5472.CAN-15-2770.", "ArticleIdList": ["10.1158/0008-5472.CAN-15-2770", "PMC5052827", "26719528"]}, {"Citation": "Ma JH, Qin L, Li X. Role of STAT3 signaling pathway in breast cancer. Cell Commun. Signal. 2020;18:33. doi: 10.1186/s12964-020-0527-z.", "ArticleIdList": ["10.1186/s12964-020-0527-z", "PMC7048131", "32111215"]}, {"Citation": "Segatto, I., Baldassarre, G. & Belletti, B. STAT3 in breast cancer onset and progression: a matter of time and context. Int. J. Mol. Sci.19 (2018).", "ArticleIdList": ["PMC6163512", "30231553"]}, {"Citation": "Yates LR, et al. Genomic evolution of breast cancer metastasis and relapse. Cancer Cell. 2017;32:169\u2013184 e7. doi: 10.1016/j.ccell.2017.07.005.", "ArticleIdList": ["10.1016/j.ccell.2017.07.005", "PMC5559645", "28810143"]}, {"Citation": "Walsh LA, et al. An integrated systems biology approach identifies TRIM25 as a key determinant of breast cancer metastasis. Cell Rep. 2017;20:1623\u20131640. doi: 10.1016/j.celrep.2017.07.052.", "ArticleIdList": ["10.1016/j.celrep.2017.07.052", "PMC5985663", "28813674"]}, {"Citation": "Cosgrove N, et al. Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities. Nat. Commun. 2022;13:514. doi: 10.1038/s41467-022-27987-5.", "ArticleIdList": ["10.1038/s41467-022-27987-5", "PMC8791982", "35082299"]}, {"Citation": "Lawson CD, et al. Rho GTPase transcriptome analysis reveals oncogenic roles for rho GTPase-activating proteins in basal-like breast cancers. Cancer Res. 2016;76:3826\u20133837. doi: 10.1158/0008-5472.CAN-15-2923.", "ArticleIdList": ["10.1158/0008-5472.CAN-15-2923", "PMC4930678", "27216196"]}, {"Citation": "Humphries, B., Wang, Z. & Yang, C. Rho GTPases: big players in breast cancer initiation, metastasis and therapeutic responses. Cells9, 2167 (2020).", "ArticleIdList": ["PMC7600866", "32992837"]}, {"Citation": "Crosas-Molist E, et al. Rho GTPase signaling in cancer progression and dissemination. Physiol. Rev. 2022;102:455\u2013510. doi: 10.1152/physrev.00045.2020.", "ArticleIdList": ["10.1152/physrev.00045.2020", "34541899"]}, {"Citation": "Razavi P, et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell. 2018;34:427\u2013438.e6. doi: 10.1016/j.ccell.2018.08.008.", "ArticleIdList": ["10.1016/j.ccell.2018.08.008", "PMC6327853", "30205045"]}, {"Citation": "Li Q, et al. INK4 tumor suppressor proteins mediate resistance to CDK4/6 kinase inhibitors. Cancer Discov. 2022;12:356\u2013371. doi: 10.1158/2159-8290.CD-20-1726.", "ArticleIdList": ["10.1158/2159-8290.CD-20-1726", "PMC8831444", "34544752"]}, {"Citation": "Rohatgi R, et al. The interaction between N-WASP and the Arp2/3 complex links Cdc42-dependent signals to actin assembly. Cell. 1999;97:221\u2013231. doi: 10.1016/S0092-8674(00)80732-1.", "ArticleIdList": ["10.1016/S0092-8674(00)80732-1", "10219243"]}, {"Citation": "Suraneni P, et al. The Arp2/3 complex is required for lamellipodia extension and directional fibroblast cell migration. J. Cell Biol. 2012;197:239\u2013251. doi: 10.1083/jcb.201112113.", "ArticleIdList": ["10.1083/jcb.201112113", "PMC3328382", "22492726"]}, {"Citation": "Hetrick B, Han MS, Helgeson LA, Nolen BJ. Small molecules CK-666 and CK-869 inhibit actin-related protein 2/3 complex by blocking an activating conformational change. Chem. Biol. 2013;20:701\u2013712. doi: 10.1016/j.chembiol.2013.03.019.", "ArticleIdList": ["10.1016/j.chembiol.2013.03.019", "PMC3684959", "23623350"]}, {"Citation": "Katayama R, et al. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res. 2013;73:3087\u20133096. doi: 10.1158/0008-5472.CAN-12-3256.", "ArticleIdList": ["10.1158/0008-5472.CAN-12-3256", "PMC3759033", "23598276"]}, {"Citation": "Buchanan SG, et al. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol. Cancer Ther. 2009;8:3181\u20133190. doi: 10.1158/1535-7163.MCT-09-0477.", "ArticleIdList": ["10.1158/1535-7163.MCT-09-0477", "19934279"]}, {"Citation": "Gong X, et al. Aurora A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor Gene. Cancer Discov. 2019;9:248\u2013263. doi: 10.1158/2159-8290.CD-18-0469.", "ArticleIdList": ["10.1158/2159-8290.CD-18-0469", "30373917"]}, {"Citation": "Clayton NS, Ridley AJ. Targeting rho GTPase signaling networks in cancer. Front. Cell Dev. Biol. 2020;8:222. doi: 10.3389/fcell.2020.00222.", "ArticleIdList": ["10.3389/fcell.2020.00222", "PMC7145979", "32309283"]}, {"Citation": "Yang J, et al. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol. Cancer. 2019;18:26. doi: 10.1186/s12943-019-0954-x.", "ArticleIdList": ["10.1186/s12943-019-0954-x", "PMC6379961", "30782187"]}, {"Citation": "Huang B, et al. The three-way switch operation of Rac1/RhoA GTPase-based circuit controlling amoeboid-hybrid-mesenchymal transition. Sci. Rep. 2014;4:6449. doi: 10.1038/srep06449.", "ArticleIdList": ["10.1038/srep06449", "PMC4171704", "25245029"]}, {"Citation": "Graziani V, Rodriguez-Hernandez I, Maiques O, Sanz-Moreno V. The amoeboid state as part of the epithelial-to-mesenchymal transition programme. Trends Cell Biol. 2022;32:228\u2013242. doi: 10.1016/j.tcb.2021.10.004.", "ArticleIdList": ["10.1016/j.tcb.2021.10.004", "34836782"]}, {"Citation": "Wang S, Liu JC, Kim D, Datti A, Zacksenhaus E. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer. Breast Cancer Res. 2016;18:9. doi: 10.1186/s13058-015-0668-y.", "ArticleIdList": ["10.1186/s13058-015-0668-y", "PMC4717616", "26781438"]}, {"Citation": "Chung PED, et al. Modeling germline mutations in pineoblastoma uncovers lysosome disruption-based therapy. Nat. Commun. 2020;11:1825. doi: 10.1038/s41467-020-15585-2.", "ArticleIdList": ["10.1038/s41467-020-15585-2", "PMC7156401", "32286280"]}, {"Citation": "Brueffer C, et al. The mutational landscape of the SCAN-B real-world primary breast cancer transcriptome. EMBO Mol. Med. 2020;12:e12118. doi: 10.15252/emmm.202012118.", "ArticleIdList": ["10.15252/emmm.202012118", "PMC7539222", "32926574"]}, {"Citation": "Carrot-Zhang J, et al. Comprehensive analysis of genetic ancestry and its molecular correlates in cancer. Cancer Cell. 2020;37:639\u2013654.e6. doi: 10.1016/j.ccell.2020.04.012.", "ArticleIdList": ["10.1016/j.ccell.2020.04.012", "PMC7328015", "32396860"]}, {"Citation": "Jiang YZ, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35:428\u2013440.e5. doi: 10.1016/j.ccell.2019.02.001.", "ArticleIdList": ["10.1016/j.ccell.2019.02.001", "30853353"]}, {"Citation": "Li J, et al. Molecular differences between screen-detected and interval breast cancers are largely explained by PAM50 subtypes. Clin. Cancer Res. 2017;23:2584\u20132592. doi: 10.1158/1078-0432.CCR-16-0967.", "ArticleIdList": ["10.1158/1078-0432.CCR-16-0967", "27587435"]}, {"Citation": "Tobin NP, et al. Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. Ann. Oncol. 2015;26:81\u201388. doi: 10.1093/annonc/mdu498.", "ArticleIdList": ["10.1093/annonc/mdu498", "PMC4269343", "25361981"]}, {"Citation": "Lopez-Ferrando V, Gazzo A, de la Cruz X, Orozco M, Gelpi JL. PMut: a web-based tool for the annotation of pathological variants on proteins, 2017 update. Nucleic Acids Res. 2017;45:W222\u2013W228. doi: 10.1093/nar/gkx313.", "ArticleIdList": ["10.1093/nar/gkx313", "PMC5793831", "28453649"]}, {"Citation": "Deng T, et al. shRNA kinome screen identifies TBK1 as a therapeutic target for HER2+ breast cancer. Cancer Res. 2014;74:2119\u20132130. doi: 10.1158/0008-5472.CAN-13-2138.", "ArticleIdList": ["10.1158/0008-5472.CAN-13-2138", "24487029"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "6", "Day": "22"}, {"Year": "2023", "Month": "6", "Day": "16"}, {"Year": "2023", "Month": "7", "Day": "21", "Hour": "6", "Minute": "44"}, {"Year": "2023", "Month": "7", "Day": "19", "Hour": "1", "Minute": "6"}, {"Year": "2023", "Month": "7", "Day": "18", "Hour": "23", "Minute": "15"}, {"Year": "2023", "Month": "7", "Day": "18"}], "PublicationStatus": "epublish", "ArticleIdList": ["37463901", "PMC10354065", "10.1038/s41467-023-39935-y", "10.1038/s41467-023-39935-y"]}}], "PubmedBookArticle": []}